| 000 | 04833nam a22004575i 4500 | ||
|---|---|---|---|
| 001 | 978-3-642-20910-9 | ||
| 003 | DE-He213 | ||
| 005 | 20140220083802.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 110719s2011 gw | s |||| 0|eng d | ||
| 020 |
_a9783642209109 _9978-3-642-20910-9 |
||
| 024 | 7 |
_a10.1007/978-3-642-20910-9 _2doi |
|
| 050 | 4 | _aQR186.7-186.85 | |
| 072 | 7 |
_aMJCM _2bicssc |
|
| 072 | 7 |
_aMED044000 _2bisacsh |
|
| 082 | 0 | 4 |
_a616.0798 _223 |
| 082 | 0 | 4 |
_a571.967 _223 |
| 100 | 1 |
_aKontermann, Roland E. _eeditor. |
|
| 245 | 1 | 0 |
_aBispecific Antibodies _h[electronic resource] / _cedited by Roland E. Kontermann. |
| 264 | 1 |
_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg : _bImprint: Springer, _c2011. |
|
| 300 |
_aXVII, 373 p. 71 illus., 36 illus. in color. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 505 | 0 | _aJanice M. Reichert: Foreword -- Roland Kontermann: Bispecific antibodies: developments and current perspectives -- Gerd Moldenhauer: Bispecific antibodies from hybrid hybridoma -- Diego Ellerman & Justin Scheer: Generation of bispecific antibodies by chemical conjugation -- Christoph Stein, Ingo Schubert & Georg Fey: Trivalent and trispecific antibody derivatives for cancer therapy -- Dafne Müller & Roland Kontermann: Diabodies, single-chain diabodies and their derivatives -- Patrick Chames & Daniel Baty: Bispecific single domain antibodies -- John Löfblom & Fredrik Y. Frejd: Alternative scaffolds as bispecific antibody mimetics -- Nico Mertens: Tribodies: building trispecificity by Fab-scFv fusions -- Pei Jin & Zhenping Zhu: The design and engineering of IgG-like bispecific antibodies -- Edit Tarcsa, Wolfgang Fraunhofer, Tariq Ghayur, Jochen Salfeld & Jijie Gu: Dual-variable-domain immunoglobulin (DVD-IgTM) technology: a versatile, novel format for the next generation of dual-targeting biologics -- Patrick Koenig & Germaine Fuh: Two-in-one antibodies -- Chien-Hsing Chang, Edmund A. Rossi, Robert Sharkey & David M. Goldenberg: The Dock-and-Lock (DNL) approach to novel bispecifc antibodies -- Christian Kellner, Matthias Peipp & Thomas Valerius: Effector cell recruitment by bispecific antibodies -- Lawrence Lum & Archana Thakur: Bispecific anibodies for arming activated T cells and other effector cells for tumor therapy -- Patrick Baeuerle, Gerhard Zugmaier & Dominik Rüttinger: Bispecific T cell engager for cancer therapy -- Horst Lindhofer, Jürgen Hess & Peter Ruf: Trifunctional Triomab® antibodies for cancer therapy -- Bruno Robert, Christel Larbouret, David Azria, Jean-Pierre Mach & André Pèlegrin: Bispecific antibodies for the retargeting of cytokines -- Dirk Nettelbeck: Bispecific antibodies and gene therapy -- Archana Parashar, Susmita Sarkar, Advaita Ganguly, Saikiran Sharma & Mavanur R. Suresh: Bispecific antibodies for diagnostic applications. | |
| 520 | _aThe concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed more than 25 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. A deeper understanding of effector cell biology and especially developments in the field of antibody engineering has led to the generation of new classes of bispecific antibodies capable of circumventing many of these obstacles. Furthermore, new applications were established for bispecific antibodies, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy. In this book, the different means of generating bispecific antibodies are described, with an emphasis on recombinant formats, and information on the various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies, but also on emerging applications such as dual targeting strategies, i.e., the simultaneous inhibition of two targets (cytokines, receptors, etc.) are provided. This book is intended for a broad readership in the field of antibody engineering, mainly from the pharmaceutical and biotechnology sector, but also including academic researchers working in this field. | ||
| 650 | 0 | _aMedicine. | |
| 650 | 0 | _aOncology. | |
| 650 | 0 | _aMonoclonal antibodies. | |
| 650 | 1 | 4 | _aBiomedicine. |
| 650 | 2 | 4 | _aAntibodies. |
| 650 | 2 | 4 | _aCancer Research. |
| 650 | 2 | 4 | _aOncology. |
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer eBooks | |
| 776 | 0 | 8 |
_iPrinted edition: _z9783642209093 |
| 856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-3-642-20910-9 |
| 912 | _aZDB-2-SBL | ||
| 999 |
_c107868 _d107868 |
||